title: Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010.
abstract: The presence of transmitted drug resistance (TDR) in treatment-naive HIV-1-positive subjects is of concern, especially in the countries of the former Soviet Union in which the number of subjects exposed to antiretrovirals (ARV) has exponentially increased during the past decade. We assessed the rate of TDR among newly diagnosed subjects in Estonia in 2010 and compared it to that in 2008. The study included 325 subjects (87% of all subjects tested HIV positive from January 1 to December 31, 2010). Of the 244 sequenced viral genomic RNA in the reverse transcriptase (RT) region 214 were CRF06_cpx, nine were subtype A1, three (one each) were subtype B and subtype C, CRF02_AG, and CRF03_AB; 15 viruses remained unclassified as putative recombinant forms between CRF06_cpx and subtype A1. HIV-1 TDR mutations in 2010 and 2008 (n=145) occurred at similar frequency in 4.5% (95% CI 2.45; 7.98) and 5.5% (95% CI 1.8; 9.24) of the patients, respectively. In 2010, 2.5% (6/244) of the sequences harbored nonnucleoside reverse transcriptase inhibitor (NNRTI) (K103N and K101E), 1.6% (4/244) nucleoside reverse transcriptase inhibitor (NRTI) (M41L, M184I, and K219E), and 0.4% (1/244) protease inhibitor (PI) (V82A) mutations. Our findings indicate that in spite of the increased consumption of ARVs the rate of TDR in Estonia has remained unchanged over the past 3 years. Similar stabilizing or even decreasing trends have been described in Western Europe and North America albeit at higher levels and in different socioeconomic backgrounds.
authors.affiliation: 1 Department of Microbiology, Faculty of Medicine, University of Tartu , Tartu, Estonia .
authors.forename: Radko
authors.initials: R
authors.lastname: Avi
authors.forename: Kristi
authors.initials: K
authors.lastname: Huik
authors.forename: Merit
authors.initials: M
authors.lastname: Pauskar
authors.forename: Valentina
authors.initials: V
authors.lastname: Ustina
authors.forename: Tõnis
authors.initials: T
authors.lastname: Karki
authors.forename: Eveli
authors.initials: E
authors.lastname: Kallas
authors.forename: Ene-Ly
authors.initials: EL
authors.lastname: Jõgeda
authors.forename: Tõnu
authors.initials: T
authors.lastname: Krispin
authors.forename: Irja
authors.initials: I
authors.lastname: Lutsar
mesh_terms: D000328:Adult; D024882:Drug Resistance, Viral; D004957:Estonia / Q000453:epidemiology; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000453:epidemiology / Q000635:transmission* / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D020125:Mutation, Missense; D015995:Prevalence; D012367:RNA, Viral / Q000235:genetics; D017422:Sequence Analysis, DNA
chemical_list: D012367:RNA, Viral; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase
references.citation: AIDS Res Hum Retroviruses. 2002 Aug 10;18(12):891-5
references.pmid: 12201913
references.citation: J Infect Dis. 2009 Nov 15;200(10):1503-8
references.pmid: 19835478
references.citation: Scand J Infect Dis. 2011 Feb;43(2):122-8
references.pmid: 20964489
references.citation: AIDS Res Hum Retroviruses. 2010 Apr;26(4):395-400
references.pmid: 20377421
references.citation: J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):598-605
references.pmid: 16044014
references.citation: J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):523-9
references.pmid: 17031320
references.citation: AIDS Res Hum Retroviruses. 2004 Nov;20(11):1148-56
references.pmid: 15588336
references.citation: Cent Eur J Public Health. 2008 Sep;16(3):138-40
references.pmid: 18935781
references.citation: J Med Virol. 2012 Jul;84(7):1002-8
references.pmid: 22585715
references.citation: J Med Virol. 2010 Dec;82(12):2013-8
references.pmid: 20981787
references.citation: AIDS Res Hum Retroviruses. 2010 Oct;26(10):1109-13
references.pmid: 20849300
references.citation: HIV Med. 2010 Aug;11(7):432-8
references.pmid: 20146736
references.citation: Brief Bioinform. 2008 Jul;9(4):299-306
references.pmid: 18417537
references.citation: J Infect Dis. 2011 Apr 15;203(8):1174-81
references.pmid: 21451005
references.citation: J Med Virol. 2005 Nov;77(3):337-44
references.pmid: 16173024
references.citation: AIDS. 2007 Oct 18;21(16):2223-9
references.pmid: 18090050
references.citation: AIDS Res Hum Retroviruses. 2006 May;22(5):470-6
references.pmid: 16706626
references.citation: PLoS One. 2009;4(3):e4724
references.pmid: 19266092
references.citation: N Engl J Med. 2002 Aug 8;347(6):385-94
references.pmid: 12167680
references.citation: Antivir Ther. 2006;11(8):1031-9
references.pmid: 17302373
references.citation: BMJ. 2012 Aug 21;345:e5253
references.pmid: 22915687
references.citation: AIDS Res Hum Retroviruses. 2006 Aug;22(8):709-14
references.pmid: 16910825
references.citation: AIDS Res Hum Retroviruses. 2006 Aug;22(8):796-800
references.pmid: 16910836
references.citation: J Med Virol. 2009 Jun;81(6):953-8
references.pmid: 19382254
references.citation: AIDS Res Hum Retroviruses. 2011 Aug;27(8):841-51
references.pmid: 21142588